{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:45:11Z","timestamp":1791229511541,"version":"4.1.0"},"reference-count":36,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"\n BACKGROUND AND OBJECTIVES:<\/jats:title>\n Recent studies show that long-term (LT) antithyroid drugs reduce relapse of hyperthyroidism in patients with Graves\u2019 disease. Our objective was to evaluate the effectiveness and safety of LT methimazole treatment and to compare remission rates in Graves' disease patients after LT and short-term (ST) therapy.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n In this randomized, parallel group trial, 66 consecutive patients with untreated juvenile Graves\u2019 hyperthyroidism were enrolled. After a median 22 months of methimazole treatment, 56 patients were randomly assigned to either continue low-dose methimazole treatment (n = 24, LT group) or to discontinue treatment (n = 24, ST group). Twenty-four patients in LT group completed 96 to 120 months of methimazole treatment. Patients in both groups were managed for 48 months after discontinuation of treatment.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n Except for 3 cases of cutaneous reactions, no other adverse events were observed throughout 120 months of methimazole therapy. Serum free thyroxine, triiodothyronine, thyrotropin, and thyrotropin receptor antibody remained normal, and the required daily dosage of methimazole was gradually decreased from 5.17 \u00b1 1.05 mg at 22 months to 3.5 \u00b1 1.3 mg between 96 and 120 months of treatment (P &lt; .001). Hyperthyroidism was cured in 92% and 88% of LT patients and in 46% and 33% of ST patients, 1 and 4 years after methimazole withdrawal, respectively.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n LT methimazole treatment of 96 to 120 months is safe and effective for treatment of juvenile Graves\u2019 disease. The four-year cure rate of hyperthyroidism with LT methimazole treatment is almost 3 times more than that of ST methimazole treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2018-3034","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T12:25:51Z","timestamp":1556627151000},"source":"Crossref","is-referenced-by-count":38,"title":["Long-term Methimazole Therapy in Juvenile Graves\u2019 Disease: A Randomized Trial"],"prefix":"10.1542","volume":"143","author":[{"given":"Fereidoun","family":"Azizi","sequence":"first","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miralireza","family":"Takyar","sequence":"additional","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Madreseh","sequence":"additional","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; and"},{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieh","family":"Amouzegar","sequence":"additional","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"2021121013164028100_B1","first-page":"987","volume-title":"Werner and Ingbar\u2019s the Thyroid","author":"LaFranchi","year":"2000","edition":"8th ed."},{"issue":"2","key":"2021121013164028100_B2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0022-3476(77)80843-3","article-title":"Antithyroid drug therapy for toxic diffuse goiter (Graves disease): thirty years experience in children and adolescents.","volume":"91","author":"Barnes","year":"1977","journal-title":"J Pediatr"},{"key":"2021121013164028100_B3","first-page":"71","article-title":"Graves\u2019 disease in children.","volume":"5","author":"Fisher","year":"1994","journal-title":"Curr Ther Endocrinol Metab"},{"key":"2021121013164028100_B4","first-page":"50","article-title":"Hyperthyroidism in childhood: causes, when and how to treat.","volume":"5","author":"L\u00e9ger","year":"2013","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"9","key":"2021121013164028100_B5","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1210\/jc.2003-031223","article-title":"A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves\u2019 patients.","volume":"89","author":"Read","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2021121013164028100_B6","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EJE-16-0938","article-title":"Management of endocrine disease: arguments for the prolonged use of antithyroid drugs in children with Graves\u2019 disease.","volume":"177","author":"L\u00e9ger","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2021121013164028100_B7","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2007-1535","article-title":"Predicting the likelihood of remission in children with Graves\u2019 disease: a prospective, multicenter study.","volume":"121","author":"Glaser","year":"2008","journal-title":"Pediatrics"},{"issue":"10","key":"2021121013164028100_B8","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1210\/jc.2008-0842","article-title":"Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment.","volume":"93","author":"Kaguelidou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2021121013164028100_B9","first-page":"1249","article-title":"Pediatric Graves\u2019 disease: outcome and treatment.","volume":"16","author":"Gru\u00f1eiro-Papendieck","year":"2003","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2021121013164028100_B10","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1210\/jcem-60-5-1019","article-title":"Management of hyperthyroidism in children and adolescents.","volume":"60","author":"Hamburger","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2021121013164028100_B11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1210\/jc.2006-2321","article-title":"Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism.","volume":"92","author":"Metso","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2021121013164028100_B12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2307\/3578322","article-title":"Issues and epidemiological evidence regarding radiation-induced thyroid cancer.","volume":"131","author":"Shore","year":"1992","journal-title":"Radiat Res"},{"issue":"6","key":"2021121013164028100_B13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/105072504323150769","article-title":"Surgical treatment of Graves\u2019 disease in children.","volume":"14","author":"Sugino","year":"2004","journal-title":"Thyroid"},{"issue":"2","key":"2021121013164028100_B14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/jpem-2017-0394","article-title":"Management of thyrotoxicosis in children and adolescents: 35 years\u2019 experience in 304 patients.","volume":"31","author":"Azizi","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"2021121013164028100_B15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1210\/jc.2011-1944","article-title":"Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves\u2019 disease: national long-term cohort study.","volume":"97","author":"L\u00e9ger","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2021121013164028100_B16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1210\/jcem-64-6-1241","article-title":"Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years.","volume":"64","author":"Lippe","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2021121013164028100_B17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2016.0652","article-title":"Long-term antithyroid drug treatment: a systematic review and meta-analysis.","volume":"27","author":"Azizi","year":"2017","journal-title":"Thyroid"},{"issue":"4","key":"2021121013164028100_B18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/thy.2011.0156","article-title":"Eighteen years of continuously sustained elimination of iodine deficiency in the Islamic Republic of Iran: the vitality of periodic monitoring.","volume":"22","author":"Delshad","year":"2012","journal-title":"Thyroid"},{"key":"2021121013164028100_B19","first-page":"369","article-title":"Technique of endemic goitre surveys.","volume":"44","author":"Perez","year":"1960","journal-title":"Monogr Ser World Health Organ"},{"issue":"1","key":"2021121013164028100_B20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jcem-44-1-203","article-title":"Modification of the classification of the eye changes of Graves\u2019 disease: recommendations of the Ad Hoc Committee of the American Thyroid Association.","volume":"44","author":"Werner","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2021121013164028100_B21","first-page":"950","article-title":"Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study.","volume":"36","author":"Amouzegar","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2021121013164028100_B22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-70-3-675","article-title":"Antithyroid drugs and Graves\u2019 disease: a prospective randomized evaluation of the efficacy of treatment duration.","volume":"70","author":"Allannic","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2021121013164028100_B23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0889-8529(05)70302-9","article-title":"Thyrotoxicosis in children.","volume":"27","author":"Zimmerman","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2021121013164028100_B24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","article-title":"Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine.","volume":"152","author":"Azizi","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2021121013164028100_B25","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","article-title":"Long-term follow-up of patients with hyperthyroidism due to Graves\u2019 disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.","volume":"31","author":"Mazza","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2021121013164028100_B26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/eje.1.02295","article-title":"Remission of Graves\u2019 disease during anti-thyroid drug therapy. Time to reconsider the mechanism?","volume":"155","author":"Laurberg","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2021121013164028100_B27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/105072501750302886","article-title":"Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves\u2019 disease.","volume":"11","author":"Zantut-Wittmann","year":"2001","journal-title":"Thyroid"},{"issue":"1","key":"2021121013164028100_B28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/endo.139.1.5658","article-title":"Regulation of major histocompatibility class II gene expression in FRTL-5 thyrocytes: opposite effects of interferon and methimazole.","volume":"139","author":"Montani","year":"1998","journal-title":"Endocrinology"},{"issue":"4","key":"2021121013164028100_B29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1515\/JPEM.1999.12.4.537","article-title":"Factors at onset predictive of lasting remission in pediatric patients with Graves\u2019 disease followed for at least three years.","volume":"12","author":"Mussa","year":"1999","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2021121013164028100_B30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1089\/thy.1997.7.755","article-title":"Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy.","volume":"7","author":"Shulman","year":"1997","journal-title":"Thyroid"},{"issue":"5","key":"2021121013164028100_B31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jpeds.2013.12.047","article-title":"Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.","volume":"164","author":"Gastaldi","year":"2014","journal-title":"J Pediatr"},{"issue":"1","key":"2021121013164028100_B32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.294.1.71","article-title":"Thyroid function and mortality in patients treated for hyperthyroidism.","volume":"294","author":"Franklyn","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"2021121013164028100_B33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2265.2007.03064.x","article-title":"Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism.","volume":"68","author":"Metso","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2021121013164028100_B34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archinte.160.4.526","article-title":"The Colorado thyroid disease prevalence study.","volume":"160","author":"Canaris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"1","key":"2021121013164028100_B35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/ncpendmet0019","article-title":"Is long-term methimazole therapy as effective as radioiodine for treating hyperthyroidism?","volume":"1","author":"Toft","year":"2005","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"8","key":"2021121013164028100_B36","first-page":"477","article-title":"Long-term continuous methimazole or radioiodine treatment for hyperthyroidism.","volume":"15","author":"Azizi","year":"2012","journal-title":"Arch Iran Med"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-3034\/1076736\/peds_20183034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-3034\/1076736\/peds_20183034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T02:14:38Z","timestamp":1639188878000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/143\/5\/e20183034\/37093\/Long-term-Methimazole-Therapy-in-Juvenile-Graves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,1]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2018-3034","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"article-number":"e20183034"}}